Amgen said its experimental weight loss injection helped patients lose up to 20% of their weight on average after a year, with no plateau, in a critical mid-stage trial. But shares of Amgen fell ...

Thousand Oaks, California-based Amgen Inc. (AMGN) discovers, develops, and manufactures innovative medicines aimed at improving the lives of millions. With a market cap of $142 billion ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

The latest trading session saw Amgen (AMGN) ending at $267.10, denoting a -1.14% adjustment from its last day's close. The stock fell short of the S&P 500, which registered a gain of 0.12% for the ...

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amgen's market standing. Stay informed and make well-considered decisions with our ...

Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain. Despite high debt from the Horizon Therapeutics acquisition, Amgen ...

Since my previous article, shares of Amgen meaningfully lagged the S&P 500 index. The company's revenue and non-GAAP EPS climbed higher in the third quarter. Amgen's deleveraging efforts are ...

However, things aren't all that rosy. In the last five years, Amgen's earnings per share has shrunk at approximately 9.7% per annum. If earnings continue declining, the company may have to make ...